DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.
Breast cancer
Prognostic markers
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
07
2019
accepted:
02
01
2020
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
7
2
2020
Statut:
epublish
Résumé
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan-Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined institutional and IBCSG chemotherapy cohorts (100 marker panel,
Identifiants
pubmed: 32025567
doi: 10.1038/s41523-020-0145-3
pii: 145
pmc: PMC6994477
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222779
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214183
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsS.S. has received research grants from the AVON Foundation and the Department of Defense, grants, licensing/royalty fees and consulting fees from Cepheid for QM-MSP and cMethDNA assays. M.J.F. has received licensing/royalty fees and consulting fees from Cepheid. No other authors have disclosed any conflicts of interest.
Références
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Lab Invest. 2008 Apr;88(4):430-40
pubmed: 18305565
Mol Oncol. 2015 Mar;9(3):555-68
pubmed: 25468711
Nat Commun. 2015 Feb 02;6:5899
pubmed: 25641231
J Clin Oncol. 2010 Apr 10;28(11):1829-34
pubmed: 20212256
Oncogene. 2001 Jun 7;20(26):3348-53
pubmed: 11423985
Cancer Res. 2004 Jul 1;64(13):4442-52
pubmed: 15231653
Cancer Res. 2016 Jun 15;76(12):3446-50
pubmed: 27256564
J Clin Oncol. 2010 Jun 20;28(18):2966-73
pubmed: 20458051
J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92
pubmed: 16954471
Clin Med Insights Oncol. 2018 Jul 27;12:1179554918790563
pubmed: 30083066
J Natl Cancer Inst. 2001 Jan 17;93(2):112-20
pubmed: 11208880
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
J Clin Oncol. 2017 Mar;35(7):751-758
pubmed: 27870562